As DNA repair is intricately connected to the development of drug resistance in tumor cells 46, it could be inferred that PRDX1 may influence the sensitivity of EGFR-TKI treatment in LUAD patients via genomic instability. The gene discussed is PRDX1; the disease is neoplasm.